Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7300860 | 0.85 | SLC13A5 (0.56) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL419615 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL10941763 | 0.83 | SLC13A5 (0.54) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL9554595 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL9554586 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL559795 | 0.80 | CTBP2 (0.54) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL559796 | 0.80 | CTBP2 (0.54) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL3730337 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL10029379 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 | |
| SCHEMBL10029155 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1AFDPSCYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868187-B2 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO., INC. (JP) | 2011-01-11 | — | — | US | claimed |
| US-20090259052-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | AJINOMOTO CO. INC (JP) | 2009-10-15 | — | — | US | claimed |
| US-7432100-B2 | Variant aldolase and processes for producing an optically active IHOG and an optically active monatin using the same | AJINOMOTO CO., INC. (JP) | 2008-10-07 | — | — | US | claimed |
| US-20050244939-A1 | Variant aldolase and processes for producing an optically active IHOG and an optically active monatin using the same | AJINOMOTO CO., INC. (JP) | 2005-11-03 | — | — | US | claimed |
| US-20050153405-A1 | Novel aldolase and production process of substituted alpha-keto acids | AJINOMOTO CO., INC. (JP) | 2005-07-14 | — | — | US | claimed |
| EP-1533376-A1 | NOVEL ALDOLASES AND PROCESS FOR PRODUCING SUBSTITUTED ALPHA-KETO ACID | Ajinomoto Co., Inc. (JP) | 2005-05-25 | — | — | EP | claimed |
| US-8697416-B2 | Recombinant polynucleotide, host cells containing the same and a process for producing a protein having aldolase activity | AJINOMOTO CO., INC. (JP) | 2014-04-15 | — | — | US | disclosed |
| US-8669080-B2 | Mutated D-aminotransferase and method for producing optically active glutamic acid derivatives using the same | AJINOMOTO CO., INC. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8563278-B2 | Process of producing glutamate derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563278-B2 | Process of producing glutamate derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563278-B2 | Process of producing glutamate derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-1580268-B1 | MUTANT D-AMINOTRANSFERASE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE GLUTAMIC ACID DERIVATIVE USING THE SAME | AJINOMOTO KK (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20130252310-A1 | NOVEL ALDOLASE AND PRODUCTION PROCESS OF SUBSTITUTED ALPHA-KETO ACIDS | AJINOMOTO, CO., INC. (JP) | 2013-09-26 | — | — | US | disclosed |
| US-20050153405-A1 | Novel aldolase and production process of substituted alpha-keto acids | AJINOMOTO CO., INC. (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1533376-A1 | NOVEL ALDOLASES AND PROCESS FOR PRODUCING SUBSTITUTED ALPHA-KETO ACID | Ajinomoto Co., Inc. (JP) | 2005-05-25 | — | — | EP | disclosed |
| CN-1610658-A | Process for producing glutamic acid compound and intermediate for producing the same, and novel intermediate for use therein | AJINOMOTO KK (JP) | 2005-04-27 | — | — | CN | disclosed |
| US-20050009153-A1 | Such as 3-indolepyruvic acid by exposing tryptophan to amino acid oxidase/catalase, adjusting pH with sulfuric acid, then deaerating/deoxygenating | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050004394-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | AJINOMOTO CO. IN (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1466890-A1 | PROCESSES FOR THE PREPARATION OF GLUTAMIC ACID COMPOUNDS AND INTERMEDIATES THEREOF AND NOVEL INTERMEDIATES USED IN THE PROCESSES | Ajinomoto Co., Inc. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1445323-A1 | PROCESS FOR PRODUCTION OF GLUTAMIC ACID DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004394-A1 | Processes of producing glutamic acid compounds and production intermediates therefore and novel intermediate for the processes | GLUL, MON2, GRIK5 | SMN1; SMN2 2414/4885HIF1A 4218/4885FDPS 382/4885 |
| US-20050244939-A1 | Variant aldolase and processes for producing an optically active IHOG and an optically active monatin using the same | ALDOA, MON2, HOGA1 | SMN1; SMN2 2260/4885HIF1A 2150/4885FDPS 927/4885 |
| US-20090259052-A1 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES | GLUL, MON2, GRIK5 | SMN1; SMN2 2414/4885HIF1A 4218/4885FDPS 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.